To Get Help Now
Click Here
 
Today's Date:

Johnson & Johnson’s Risperdal Under Fire for $1 billion For Off-Label Uses

AddThis Social Bookmark Button

Since 2004 the federal government has been investigating whether Johnson & Johnson’s Janssen Pharmaceutica improperly promoted Risperdal, an antipsychotic drug, for unapproved used.

Johnson & Johnson has confirmed they have been in ongoing discussions with the government. A recent filing by the company claims it has  set aside an undisclosed amount to settle potential civil and criminal charges. It’s going to need it.

Federal prosecutors are seeking $1 billion, among the largest settlements in the industry’s history, and one that will likely effect Johnson & Johnson’s quarterly financials. That number was based off of a 2009 settlement where Eli Lilly & Co paid $1.4 billion to resolve improper marketing investigations of its Zyprexa anti-psychotic drug.

breakinglawsuitnews.com disclaimer: This article: Johnson & Johnson’s Risperdal Under Fire for $1 billion For Off-Label Uses was posted on Friday, May 13th, 2011 at 7:47 pm at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.